PREPARATION AND EVALUATION OF ATENOLOL-Î²-CYCLODEXTRIN ORALLY DISINTEGRATING TABLETS USING CO-PROCESS CROSPOVIDONE-SODIUM STARCH GLYCOLATE
Objective: The aim of this current research was to formulate and analyze the characteristics of atenolol-Î²-cyclodextrin which using co-process crospovidone-sodium starch glycolate as the disintegrants. Evaluation which has been conducted on orally disintegrating tablets consist of wetting time, water absorption ratio, in vitro dispersion time, and dissolution.
Methods: Inclusion complex of atenolol-Î²-cyclodextrin which were prepared using solvent evaporation method, then formulated using co-processed crospovidone-sodium starch glycolate 1:1 (formula 1) and 1:2 (formula 2) into orally disintegrating tablets by direct compression technique. Orally disintegrating tablets of atenolol-Î²-cyclodextrin using a physical mixture of crospovidone-sodium starch glycolate 1:1 (formula 3), 1:2 (formula 4) was also prepared as a control. The prepared formulations (F1-F4) were evaluated by several parameters such as wetting time, water absorption ratio, in vitro dispersion time, and dissolution.
Results: Orally disintegrating tablets of atenolol-Î²-cyclodextrin using co-processed crospovidone-sodium starch glycolate 1:1 (formula 1) showed shorter wetting time (53.53Â±2.26 seconds) and in vitro dispersion time (47.44Â±2.49 seconds) compare to the other formulas. Formula 1 also exhibited the highest dissolution efficiency compare to the formula which was used in the physical mixture. The results of this study also revealed that there was a high correlation between in vitro dispersion time and dissolution efficiency of atenolol-Î²-cyclodextrin orally disintegrating tablets.
Conclusion: Orally disintegrating tablets of atenolol-Î²-cyclodextrin showed enhanced dissolution efficiency due to the presence of inclusion complex and co-processed crospovidone-sodium starch glycolate. Formula 1 was found to be the best formula in this study. This formula effectively reduces in vitro dispersion time, hence the dissolution efficiency became higher.
2. Sandeep DJ, Rahul NK, Chetan MJ, Bharat WT, Vijay RP. Formulation and evaluation of fast dissolving oral film of levocetirizine dihydrochloride. Int J Pharm Pharm Sci 2012;4:337-441.
3. Morris LS, Schulz RM. Patient compliance-an overview. J Clin Pharm Ther 1992;17:283-95.
4. Taj R, Khan S. A study of reasons for non-compliance to psychiatric treatment. J Ayub Med Coll Abbottabad 2005;17:26-8.
5. Hahm HA, Augsburger LL. Orally disintegrating tablets and related tablet formulations. In: Pharmaceutical Dosage Forms: Tablets. New York: Informa Healthcare; 2008. p. 293-312.
6. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: orally disintegrating tablets. New Hampshire eve: Division of drug information food and drug administration; 2008.
7. Behnke K, Sogaard J, Martin S, Baumi J, Ravindran AV, Agren H. Mirtazapine orally disintegrating tablets versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23:358-64.
8. Diaz JE, Montoya EG, Negre JM, Lozano PP, Minarro M, Tico JR. Predicting orally disintegrating tablets formulations of ibuprofen tablets: an application of the new sedem-odt expert system. Eur J Pharm Biopharm 2012;80:638-48.
9. Brown D. Orally disintegrating tablets: taste over speed. Drug Delivery Technol 2001;3:58-61.
10. Nagar P, Singh K, Chauhan I, Madhu V, Yasir M, Khan A, et al. Orally disintegrating tablets: formulation, preparation, techniques, and evaluation. J Appl Pharm Sci 2011;4:35-45.
11. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 7thed. New York: McGraw-Hill; 2008.
12. Ranch KM, Koli AR, Vyas BA, Parikh RK, Vyas RB, Maniyar NR, et al. Formulation, design, and optimization of orodispersible tablets of atenolol. Int J Pharm Tech Res 2009;1:1559-63.
13. Sweetman. Martindale the complete drug reference. 36th ed. London: Pharmaceutical Press; 2009.
14. Florey K. Analytical profiles of the drug substance. Vol. 13. Orlando: Academic Press; 1984.
15. Buha SM, Baxi GA, Shrivastav PS. Liquid chromatography study on atenolol-Î²-cyclodextrin inclusion complex. ISRN Anal Chem 2012;1:1-8.
16. Mittapalli RK, Qhattal HS, Lockman PR, Yamsani MR. Varying efficacy of super disintegrants in orally disintegrating tablets among different manufacturers. Pharmazie 2010;65:805-10.
17. Nagendrakumar D, Raju SA, Shirsand SB, Para MS. Design of fast dissolving granisetron HCl tablets using novel co-processed super disintegrants. Int J Pharm Sci Rev Res 2010;12:58-62.
18. Kumare MM, Marathe RP, Kawade RM, Ghante MH, Shendarkar RR. Design of fast dissolving tablet of atenolol using novel co-processed superdisintegrants. Asian J Pharm Clin Res 2013;6 Suppl 3:81-5.
19. United States Pharmacopeial Convention. United States Pharmacopeia 40 National Formulary 35. Rockville: United States Pharmacopeial Committee; 2017. p. 2886-8.
20. Chandrasekhar P, Shahid MS, Niranjan BM. Formulation and evaluation of oral dispersible tablets of antihypertensive drug atenolol. Int J Pharm 2013;3 Suppl 2:79â€“84.
21. Venkateswarlu K, Naik SB, Chandrasekhar KB. Formulation and in vitro evaluation of orlistat orodispersible tablets for enhancement of dissolution rate. Int J Pharm Pharm Sci 2016;8:236-41.
22. Aulton M, Summers M. In aultonâ€™s pharmaceutics the design and manufacture of medicines. Philadelphia: Churchill Livingstone; 2013. p. 187-99.
23. Avulapati S, Roy AP, Shashidhar KR, Reddy TU. Formulation and evaluation of taste masked and fast disintegrating losartan potassium tablets. Int J Drug Dev Res 2011;3:45-51.
24. Kulkarni SV, Kumar R, Basavaraj, Rao S, Ramesh B, Kumar A. Effect of superdisintegrants on the formulation of taste masked fast disintegrating lisinopril tablets. Int J Curr Pharm Res 2011;3:11-4.
25. Reddy BV, Navaneetha K, Reddy VR, Reddy PP, Reddy PU, Lavanya T. Formulation and evaluation of fast dissolving tablets of losartan potassium. Indo Am J Pharm Res 2014;4:2573-84.
26. Vijaya V, Niroosha C, Ravi M. Comparative formulation, evaluation, and optimization of imidapril mouth dissolving tablets using different synthetic superdisintegrating agents. Int J Pharm Pharm Sci 2016;8:150-6.
27. Mahendrakumar P, Liew CV, Heng PW. Review of disintegrants and disintegration phenomena. J Pharm Sci 2016;105:2545-55.
28. Preethi GB, Banerjee S, Shivakumar HN, Kumar RM. Formulation of fast dissolving tablets of doxazosin mesylate drug by direct compression method. Int J Appl Pharm 2017;9:22-8.